{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T16:52:25Z","timestamp":1791132745829,"version":"4.1.0"},"reference-count":56,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:00:00Z","timestamp":1791072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:00:00Z","timestamp":1791072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/13696998.2026.2736995","type":"journal-article","created":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T16:07:57Z","timestamp":1791130077000},"page":"2448-2463","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of etranacogene dezaparvovec compared to eftrenonacog alfa for the treatment of adult patients with severe and moderately severe haemophilia B in Sweden"],"prefix":"10.1080","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1677-3839","authenticated-orcid":false,"given":"Songkai","family":"Yan","sequence":"first","affiliation":[{"name":"CSL Behring","place":["King of Prussia, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3778-4011","authenticated-orcid":false,"given":"Olof","family":"Mogard","sequence":"additional","affiliation":[{"name":"Parexel International","place":["Z\u00fcrich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8118-446X","authenticated-orcid":false,"given":"Anna","family":"Tj\u00e4rnlund-Wolf","sequence":"additional","affiliation":[{"name":"CSL Behring AB","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Sj\u00f6\u00f6","sequence":"additional","affiliation":[{"name":"CSL Behring AB","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1046-4119","authenticated-orcid":false,"given":"Andr\u00e9","family":"Eid","sequence":"additional","affiliation":[{"name":"Parexel International","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7044-4780","authenticated-orcid":false,"given":"Jack","family":"Ettinger","sequence":"additional","affiliation":[{"name":"Parexel International","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7388-2013","authenticated-orcid":false,"given":"Douglass","family":"Drelich","sequence":"additional","affiliation":[{"name":"CSL Behring","place":["King of Prussia, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radovan","family":"Tomic","sequence":"additional","affiliation":[{"name":"CSL Behring S.p.A","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stina","family":"Johansson","sequence":"additional","affiliation":[{"name":"CSL Behring AB","place":["Stockholm, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,10,4]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14838"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"e_1_3_5_4_1","volume-title":"Report on the Annual Global Survey 2023","author":"World Federation of Hemophilia (WFH)","year":"2024","unstructured":"World Federation of Hemophilia (WFH). Report on the Annual Global Survey 2023. Montr\u00e9al, Qu\u00e9bec, Canada: World Federation of Hemophilia (WFH); 2024."},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13998"},{"key":"e_1_3_5_6_1","unstructured":"Dental and Pharmaceutical Benefits Agency (TLV). Alprolix ing\u00e5r i l\u00e4kemedelsf\u00f6rm\u00e5nerna med uppf\u00f6ljningsvillkor [Alprolix is included in the pharmaceutical benefits scheme with follow-up conditions]. Stockholm Sweden: Tandv\u00e5rds- och l\u00e4kemedelsf\u00f6rm\u00e5nsverket (TLV); 2018. Available from: https:\/\/www.tlv.se\/download\/18.703c117b1661eb30f7cac23\/1538136388008\/bes180927_alprolix.pdf."},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14704"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15424"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2021.1891088"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01774-9"},{"key":"e_1_3_5_11_1","unstructured":"Dental and Pharmaceutical Benefits Agency (TLV). FIX assessment in Sweden. https:\/\/www.tlv.se\/download\/18.2fb232d9174ba11bd5bc43d6\/1601640705396\/200924_underlag_faktor_ix.pdf; 2020."},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.70023"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.100061"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211644"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00006-1"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2514332"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1721508"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-35280-8_1934"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13185"},{"key":"e_1_3_5_20_1","unstructured":"Institute for Clinical and Economic Review (ICER). Gene therapy for hemophilia B and an update on gene therapy for hemophilia A: effectiveness and value. https:\/\/icer.org\/wp-content\/uploads\/2022\/05\/ICER_Hemophilia_Final_Report_12222022.pdf; 2022."},{"key":"e_1_3_5_21_1","unstructured":"Office for National Statistics. Overview of the UK population. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/articles\/overviewoftheukpopulation\/january2021; 2021."},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13120"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1258\/rsmacta.43.5.528"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305074"},{"key":"e_1_3_5_25_1","unstructured":"Klamroth R Bonner A Gomez K et al. Indirect comparisons of etranacogene dezaparvovec after 5 years versus extended half-life FIX therapies in haemophilia B. Manuscript submitted for publication; 2026."},{"key":"e_1_3_5_26_1","unstructured":"Statistics Sweden (SCB). Life table by sex and age. Year 1960\u20132024. https:\/\/www.statistikdatabasen.scb.se\/pxweb\/en\/ssd\/START__BE__BE0101__BE0101I\/LivslangdEttariga\/."},{"issue":"2","key":"e_1_3_5_27_1","first-page":"1319","article-title":"A Bayesian approach for selecting relevant external data (BASE): application to a study of long-term outcomes in a hemophilia gene therapy trial (HOPE-B)","volume":"20","author":"Tianyu P","year":"2026","unstructured":"Tianyu P, et al. A Bayesian approach for selecting relevant external data (BASE): application to a study of long-term outcomes in a hemophilia gene therapy trial (HOPE-B). Ann Appl Stat. 2026;20(2):1319\u20131339.","journal-title":"Ann Appl Stat"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2022.2133492"},{"key":"e_1_3_5_29_1","unstructured":"CSL Behring. HOPE-B Phase 3 study: 60-month follow-up results for etranacogene dezaparvovec in adults with haemophilia B. Data on file. King of Prussia PA USA: CSL Behring; 2026."},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.05.005"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.09.1420"},{"key":"e_1_3_5_32_1","unstructured":"Institute for Clinical and Economic Review (ICER). Emicizumab for hemophilia A with inhibitors: effectiveness and value. https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_Hemophilia_Final_Evidence_Report_041618.pdf; 2018."},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S316276"},{"key":"e_1_3_5_34_1","unstructured":"Dental and Pharmaceutical Benefits Agency (TLV). Health economic assessment of Hemgenix (etranacogene dezaparvovec). https:\/\/www.tlv.se\/download\/18.4dde4fad18affbdfb295c879\/1697025154443\/bed231011_hemgenix_2127-2022.pdf; 2023."},{"key":"e_1_3_5_35_1","unstructured":"Dental and Pharmaceutical Benefits Agency (TLV). TLV guideline and price database. https:\/\/www.tlv.se\/; 2026."},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.11.1351"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2414783"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-02152-1"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13003"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-024-00932-x"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2024.2351762"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-024-00480-z"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2024.23214"},{"key":"e_1_3_5_44_1","unstructured":"Medical Services Advisory Committee (MSAC). Application No. 1728.1\u2014etranacogene dezaparvovec for the treatment of haemophilia B. https:\/\/www.msac.gov.au\/sites\/default\/files\/2025-11\/1728.1_final_psd_-_july_2025_-_redacted.pdf; 2025."},{"key":"e_1_3_5_45_1","unstructured":"Danish Medical Council. The medical council recommends the gene therapy Hemgenix following a new effect-based price agreement. https:\/\/medicinraadet.dk\/nyheder\/2024\/medicinradet-anbefaler-genterapien-hemgenix-efter-ny-effektbaseret-prisaftale; 2024."},{"key":"e_1_3_5_46_1","unstructured":"Inter-Ministerial Pricing Commission for Pharmaceuticals (CIPM). Agreements of the interministerial commission on medicine prices (Session 249 of July 17 2024). https:\/\/www.sanidad.gob.es\/areas\/farmacia\/precios\/comisionInteministerial\/acuerdosNotasInformativas\/docs\/ACUERDOS_CIPM_249.pdf; 2024."},{"key":"e_1_3_5_47_1","unstructured":"National Institute for Health and Care Excellence (NICE). Daclizumab for treating relapsing\u2013remitting multiple sclerosis (Technology Appraisal Guidance TA441). London UK: NICE; 2017. Available from: https:\/\/www.nice.org.uk\/guidance\/ta441."},{"key":"e_1_3_5_48_1","unstructured":"Southern Healthcare Region. Regional prices and reimbursements. https:\/\/sodrasjukvardsregionen.se\/verksamhet\/regionala-priser-och-ersattningar\/; 2026."},{"key":"e_1_3_5_49_1","unstructured":"Southern Healthcare Region. Clinical chemistry price list 2026. https:\/\/vardgivare.skane.se\/siteassets\/2.-patientadministration\/avgifter-och-prislistor\/prislistor\/labmedicin\/rs\u2013-fillistning\/klinisk-kemi-och-farmakologi\u2013-for-region-skane-och-sodra-sjukvardsregionen.pdf; 2026."},{"key":"e_1_3_5_50_1","unstructured":"Apoteket AB. Apoteket. Solna Sweden: Apoteket AB; 2026. Available from:https:\/\/www.apoteket.se\/."},{"key":"e_1_3_5_51_1","unstructured":"Dental and Pharmaceutical Benefits Agency (TLV). Tandpriskollen reference price. https:\/\/tandpriskollen.se\/; 2026."},{"key":"e_1_3_5_52_1","volume-title":"Res Pract Thromb Haemost","author":"Nissen F","unstructured":"Nissen F, Burke T, Asghar S, et al. An insight into clinical outcomes in mild, moderate, and severe hemophilia A (HA): a preliminary analysis of the CHESS II study. Res Pract Thromb Haemost. 2020; Abstract OC 09.3."},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13561-018-0185-7"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X11401031"},{"key":"e_1_3_5_55_1","unstructured":"National Institute for Health and Care Excellence (NICE). Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (Technology Appraisal Guidance TA561). London: NICE; 2019. Available at: https:\/\/www.nice.org.uk\/guidance\/ta561."},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-017-0580-7"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-019-02163-3"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2736995","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/13696998.2026.2736995","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2736995","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T16:08:06Z","timestamp":1791130086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2026.2736995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,4]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/13696998.2026.2736995"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2026.2736995","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-04-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}